Infectious Disease Treatment Market in China 2016-2020

  • ID: 3752371
  • Report
  • Region: China
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Achaogen
  • AstraZeneca
  • Celsus therapeutics
  • Exoxemis
  • Gilead Sciences
  • Hexi
  • MORE
About the Infectious Disease Treatment Market in China

Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

The analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- Johnson & Johnson
- Merck
- Pfizer

Other prominent vendors
- Achaogen
- Actelion
- Adenovir Pharma
- AstraZeneca
- Bayer
- Biocryst
- Celsus therapeutics
- Cempra
- Eleven Biotherapeutics
- Exoxemis
- Ferrer International
- Griffin Discoveries
- Hexima
- InSite Vision
- Insmed Incorporated
- KaloBios Pharmaceuticals
- Lytix Biopharma
- Meiji Seika Pharma
- Melinta Therapeutics
- Moberg Pharma
- NanoViricides
- Nektar
- NicOx
- NovaBay
- NovaBiotics
- Ocular Therapeutix
- Panoptes Pharma
- Paratek Pharmaceuticals
- Polichem
- PTC Therapeutics
- RedHill
- Shire
- Starpharma Holdings
- Sun Pharma
- Symbiomix
- Tetraphase Pharmaceuticals
- The Medicines Company
- Theravance Biopharma
- Topica Pharmaceuticals
- Vertex Pharmaceuticals
- Viamet Pharmaceuticals

Market drivers
- Use of combination therapies
- For a full, detailed list, view the full report

Market challenges
- Development of drug resistant strains
- For a full, detailed list, view the full report

Market trends
- Emergence of interferon (IFN)-free therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achaogen
  • AstraZeneca
  • Celsus therapeutics
  • Exoxemis
  • Gilead Sciences
  • Hexi
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Assumptions
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: China - An overview
  • Social and economic conditions
  • Healthcare reforms
  • Healthcare infrastructure
PART 06: Opportunities for global and local vendors
  • Local vendors
  • Global vendors
PART 07: Pipeline analysis
  • AC-170
  • DEXTENZA
  • Zerbaxa
  • Surotomycin
  • MK-3415A
  • Amikacin Inhale
  • CARBAVANCE
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • VivaGel
  • Arikayce
  • Cadazolid
  • Ozenoxacin
  • TDT 067
  • MOB-015
  • 1334H
  • Auriclosene
  • EBI-005
  • FST-100
  • VT-1161
  • Luliconazole solution, 10%
  • ME1111
  • NP213
  • HXP124
  • SPL7013
  • OPX-1
  • AzaSite Xtra (ISV-405)
  • GD134
PART 08: Market landscape
  • Pharmaceutical market in China
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 09: Market segmentation by application

PART 10: Antibacterial drugs market in China
  • MOA
  • Market size and forecast
PART 11: Antiviral drugs market in China
  • Market size and forecast
  • Market segmentation by disease
  • Hepatitis C drugs market in China
  • Hepatitis B drugs market in China
  • HIV drugs market in China
PART 12: Antifungal drugs market in China
  • Market size and forecast
PART 13: Antiparasitic drugs market in China

PART 14: Market drivers
  • Climatic changes
  • Increased exposure to chemicals and pollutants
  • Use of combination therapies
  • Increased prevalence of infectious diseases
  • Increase in awareness
PART 15: Impact of drivers

PART 16: Market challenges
  • Counterfeit drugs
  • Development of drug-resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research
  • Increased use of generics and CAMs
PART 17: Impact of drivers and challenges

PART 18: Market trends
  • Increase in collaborations and M&A
  • Emergence of IFN-free therapies
  • Increase in injection drug users
PART 19: Vendor landscape
  • Competitive scenario
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Other prominent vendors
PART 20: Appendix
  • List of abbreviations
PART 21: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: China GDP 2010-2014 ($ trillions)
Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 04: Healthcare reforms in China
Exhibit 05: New drug approval (NDA) review process in China
Exhibit 06: New drug approval process in China
Exhibit 07: Drug registration classification and requirements in China
Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio
Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions)
Exhibit 10: China pharmaceutical market overview: SWOT analysis
Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015
Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions)
Exhibit 13: Venues for purchasing anti-infective drugs in China
Exhibit 14: Five forces analysis
Exhibit 15: Infectious disease treatment market in China segmentation by application
Exhibit 16: Infectious disease treatment market in China segmentation by application 2015
Exhibit 17: Infectious disease treatment market in China segmentation by application 2020
Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions)
Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage)
Exhibit 20: Infectious disease treatment market in China 2015-2020
Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020
Exhibit 22: MOA of antibacterial drugs
Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions)
Exhibit 24: Segmentation of antibacterial drugs market by chemical class
Exhibit 25: Cephalosporin segmentation by generation of drugs
Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class
Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin
Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions)
Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015
Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020
Exhibit 31: Hepatitis C drugs market in China ($ billions)
Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions)
Exhibit 33: Segmentation of hepatitis B and C market based on MOA
Exhibit 34: HIV drugs market in China ($ millions)
Exhibit 35: HIV drugs market segmentation by drug class 2015
Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions)
Exhibit 37: Antifungal drugs market in China segmentation by chemical class
Exhibit 38: Antifungal drugs market segmentation by chemical class 2015
Exhibit 39: Antiparasitic drugs market in China ($ millions)
Exhibit 40: Impact of drivers
Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance
Exhibit 42: Impact of drivers and challenges
Exhibit 43: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions)
Exhibit 44: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions)
Exhibit 45: F. Hoffmann-La F. Hoffmann-La Roche: Key takeaways
Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions)
Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions)
Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 50: Gilead Sciences: Key takeaways
Exhibit 51: GlaxoSmithKline: Key takeaways
Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (International markets) 2013-3015 ($ millions)
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions)
Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions)
Exhibit 55: Johnson & Johnson: Key takeaways
Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions)
Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions)
Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions)
Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions)
Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions)
Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions)
Exhibit 62: Merck: Key takeaways
Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions)
Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions)
Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions)
Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions)
Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions)
Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions)
Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions)
Exhibit 70: Pfizer: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Achaogen
  • AstraZeneca
  • Celsus therapeutics
  • Exoxemis
  • Gilead Sciences
  • Hexi
  • MORE
New Report Released: – Infectious Disease Treatment Market in China 2016-2020

The author of the report recognizes the following companies as the key players in the infectious disease treatment market in China: F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, and Pfizer.

Other Prominent Vendors in the market are: Achaogen, Actelion, Adenovir Pharma, AstraZeneca, Bayer, Biocryst, Celsus therapeutics, Cempra, Eleven Biotherapeutics, Exoxemis, Ferrer International, Griffin Discoveries, Hexima, InSite Vision, Insmed Incorporated, KaloBios Pharmaceuticals, Lytix Biopharma, Meiji Seika Pharma, Melinta Therapeutics, Moberg Pharma, NanoViricides, Nektar, NicOx, NovaBay, NovaBiotics, Ocular Therapeutix, Panoptes Pharma, Paratek Pharmaceuticals, Polichem, PTC Therapeutics, RedHill, Shire, Starpharma Holding, Sun Pharma, Symbiomix, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Theravance Biopharma, Topica Pharmaceuticals, Vertex Pharmaceuticals, and Viamet Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “A trend which will boost market growth is the emergence of IFN-free therapies. At present, hepatitis C treatment relies on the administration of IFN-based therapies in combination with ribavirin. Existing therapies are associated with side-effects such as anemia and leukopenia. Owing to this, researchers and vendors are focusing on developing DAAs with minimal side effects. These therapies are intended to be all-oral regimens. Once approved, they will have a positive effect on the market. For instance, Gilead Sciences is investigating Sovaldi, which received priority review approval for Hepatitis C.”

According to the report, a key growth driver is the use of combination therapies. Physicians are increasingly prescribing drugs that are a combination of an anti-infective and a corticosteroid. Anti-infectives help reduce infection while corticosteroids reduce the inflammation. Anti-infectives, when used alone, also take a longer time for disease remission. Some examples of combination drugs used to treat conjunctivitis include Neo-Poly-Dex eye drops by Bausch & Lomb and Maxitrol by Alcon, which contain polymyxin B sulfates and neomycin and dexamethasone.

Further, the report states that one challenge that could hamper market growth is the development of drug resistant strains of microbes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- Johnson & Johnson
- Merck
- Pfizer
- Achaogen
- Actelion
- Adenovir Pharma
- AstraZeneca
- Bayer
- Biocryst
- Celsus therapeutics
- Cempra
- Eleven Biotherapeutics
- Exoxemis
- Ferrer International
- Griffin Discoveries
- Hexi
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll